1. Weight loss and diabetes medication semaglutide has been linked to a significantly greater risk for repeat operations in patients with diabetes who require lumbar surgery.
2. Researchers found that postoperative complications after total hip replacement are similar between obese patients using semaglutide compared to those who are not.
3. Research has shown that diabetic patients who were taking semaglutide at time of their surgeries did not demonstrate statistically significant higher rates of complications compared with controls, had lower rates of readmission within 90 days of surgery and lower rates of prosthetic joint infection.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
